These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 28453697)
1. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Dienstmann R; Mason MJ; Sinicrope FA; Phipps AI; Tejpar S; Nesbakken A; Danielsen SA; Sveen A; Buchanan DD; Clendenning M; Rosty C; Bot B; Alberts SR; Milburn Jessup J; Lothe RA; Delorenzi M; Newcomb PA; Sargent D; Guinney J Ann Oncol; 2017 May; 28(5):1023-1031. PubMed ID: 28453697 [TBL] [Abstract][Full Text] [Related]
2. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. Roth AD; Delorenzi M; Tejpar S; Yan P; Klingbiel D; Fiocca R; d'Ario G; Cisar L; Labianca R; Cunningham D; Nordlinger B; Bosman F; Van Cutsem E J Natl Cancer Inst; 2012 Nov; 104(21):1635-46. PubMed ID: 23104212 [TBL] [Abstract][Full Text] [Related]
3. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J Ann Oncol; 2019 Oct; 30(10):1622-1629. PubMed ID: 31504112 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers. de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292 [TBL] [Abstract][Full Text] [Related]
5. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer. Chouhan H; Sammour T; Thomas ML; Moore JW J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198 [TBL] [Abstract][Full Text] [Related]
6. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391 [TBL] [Abstract][Full Text] [Related]
7. Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial. Roh CK; Choi YY; Choi S; Seo WJ; Cho M; Jang E; Son T; Kim HI; Kim H; Hyung WJ; Huh YM; Noh SH; Cheong JH Yonsei Med J; 2019 Feb; 60(2):132-139. PubMed ID: 30666834 [TBL] [Abstract][Full Text] [Related]
8. Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer. Koenig JL; Toesca DAS; Harris JP; Tsai CJ; Haraldsdottir S; Lin AY; Pollom EL; Chang DT Am J Clin Oncol; 2019 Jul; 42(7):573-580. PubMed ID: 31166206 [TBL] [Abstract][Full Text] [Related]
9. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). Singh PP; Shi Q; Foster NR; Grothey A; Nair SG; Chan E; Shields AF; Goldberg RM; Gill S; Kahlenberg MS; Sinicrope FA; Sargent DJ; Alberts SR Oncologist; 2016 Dec; 21(12):1509-1521. PubMed ID: 27881709 [TBL] [Abstract][Full Text] [Related]
10. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022 [TBL] [Abstract][Full Text] [Related]
11. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy. Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916 [TBL] [Abstract][Full Text] [Related]
12. Real-world study of a novel prognostic scoring system: for a more precise prognostication and better clinical treatment guidance in stages II and III colon cancer. Liu Q; Ma Y; Luo D; Cai S; Li Q; Li X Int J Colorectal Dis; 2018 Aug; 33(8):1107-1114. PubMed ID: 29770845 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study. Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026 [TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208 [TBL] [Abstract][Full Text] [Related]
15. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P; JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892 [TBL] [Abstract][Full Text] [Related]
16. [Prognostic value and initial exploratory research on TNM staging method of tumor deposits in stage III colon cancer]. Qin Q; Yang L; Zhou AP; Wang JW; Zhong DS Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Dec; 22(12):1152-1158. PubMed ID: 31874531 [No Abstract] [Full Text] [Related]
17. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. Watanabe T; Wu TT; Catalano PJ; Ueki T; Satriano R; Haller DG; Benson AB; Hamilton SR N Engl J Med; 2001 Apr; 344(16):1196-206. PubMed ID: 11309634 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. Tougeron D; Mouillet G; Trouilloud I; Lecomte T; Coriat R; Aparicio T; Des Guetz G; Lécaille C; Artru P; Sickersen G; Cauchin E; Sefrioui D; Boussaha T; Ferru A; Matysiak-Budnik T; Silvain C; Karayan-Tapon L; Pagès JC; Vernerey D; Bonnetain F; Michel P; Taïeb J; Zaanan A J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26839356 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of BRAF mutation alone and in combination with microsatellite instability in stage III colon cancer. Chouhan H; Sammour T; L Thomas M; W Moore J Asia Pac J Clin Oncol; 2019 Feb; 15(1):69-74. PubMed ID: 30421554 [TBL] [Abstract][Full Text] [Related]
20. Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer. Shaib WL; Zakka KM; Jiang R; Yan M; Alese OB; Akce M; Wu C; Behera M; El-Rayes BF Cancer; 2020 Sep; 126(18):4136-4147. PubMed ID: 32697360 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]